Tom Waddell

1.6k total citations · 1 hit paper
18 papers, 715 citations indexed

About

Tom Waddell is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Tom Waddell has authored 18 papers receiving a total of 715 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Tom Waddell's work include Renal cell carcinoma treatment (17 papers), Economic and Financial Impacts of Cancer (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Tom Waddell is often cited by papers focused on Renal cell carcinoma treatment (17 papers), Economic and Financial Impacts of Cancer (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Tom Waddell collaborates with scholars based in United Kingdom, United States and Canada. Tom Waddell's co-authors include Thomas Powles, Frédéric Pouliot, L. Rhoda Molife, Elizabeth R. Plimack, Brian I. Rini, Rustem Gafanov, Ray McDermott, Dmitry Nosov, V.P. Stus and Sérgio Jobim Azevedo and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Tom Waddell

17 papers receiving 700 citations

Hit Papers

Pembrolizumab plus axitinib versus sunitinib monotherapy ... 2020 2026 2022 2024 2020 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
    2020 498 citations Thomas Powles, Elizabeth R. Plimack et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tom Waddell United Kingdom 7 567 427 269 207 131 18 715
Shruti Shally Saggi United States 8 488 0.9× 389 0.9× 199 0.7× 165 0.8× 110 0.8× 9 591
Daniel Yick Chin Heng Canada 11 597 1.1× 396 0.9× 302 1.1× 261 1.3× 138 1.1× 110 759
Shaan Dudani Canada 14 536 0.9× 420 1.0× 271 1.0× 246 1.2× 141 1.1× 48 765
Sangeeta Jethwa Switzerland 5 582 1.0× 253 0.6× 480 1.8× 359 1.7× 68 0.5× 10 757
Omi Parikh United Kingdom 11 461 0.8× 226 0.5× 306 1.1× 224 1.1× 89 0.7× 34 590
Martin Eduardo Richardet Argentina 10 362 0.6× 353 0.8× 171 0.6× 126 0.6× 88 0.7× 21 501
Raffaele Ratta Italy 17 435 0.8× 327 0.8× 197 0.7× 185 0.9× 82 0.6× 65 602
Vincenzo Emanuele Chiurì Italy 12 456 0.8× 478 1.1× 213 0.8× 189 0.9× 67 0.5× 35 703
Christina Schiff United States 11 383 0.7× 309 0.7× 165 0.6× 159 0.8× 161 1.2× 16 510
Chun Loo Gan Canada 11 355 0.6× 183 0.4× 207 0.8× 153 0.7× 80 0.6× 40 468

Countries citing papers authored by Tom Waddell

Since Specialization
Citations

This map shows the geographic impact of Tom Waddell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Waddell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Waddell more than expected).

Fields of papers citing papers by Tom Waddell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Waddell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Waddell. The network helps show where Tom Waddell may publish in the future.

Co-authorship network of co-authors of Tom Waddell

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Waddell. A scholar is included among the top collaborators of Tom Waddell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Waddell. Tom Waddell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Fleeman, Nigel, Rachel Houten, Sarah J Nevitt, et al.. (2024). Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 28(49). 1–190.
2.
Rini, Brian I., Elizabeth R. Plimack, V.P. Stus, et al.. (2024). Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 42(16_suppl). 4505–4505. 8 indexed citations
3.
Arranz, José Ángel, Omi Parikh, Laura-Maria Krabbe, et al.. (2024). Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis. Current Oncology Reports. 26(12). 1639–1650. 1 indexed citations
4.
Waddell, Tom, Manon Pillai, Donna M. Graham, et al.. (2024). Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population. Future Oncology. 20(33). 2547–2558. 3 indexed citations
5.
Allison, Jennifer, Sam Wong, Helen Wong, et al.. (2023). Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis. Targeted Oncology. 18(4). 593–599. 1 indexed citations
6.
Morse, Paul T., Samuel J. Tuck, Dennis J. Goebel, et al.. (2023). Non‐invasive treatment of ischemia/reperfusion injury: Effective transmission of therapeutic near‐infrared light into the human brain through soft skin‐conforming silicone waveguides. Bioengineering & Translational Medicine. 8(3). e10496–e10496. 4 indexed citations
7.
Rini, Brian I., Elizabeth R. Plimack, V.P. Stus, et al.. (2023). Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.. Journal of Clinical Oncology. 41(17_suppl). LBA4501–LBA4501. 45 indexed citations
8.
Albigès, Laurence, Wilson H. Miller, Jeffrey C. Goh, et al.. (2023). Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.. Journal of Clinical Oncology. 41(16_suppl). 4553–4553. 6 indexed citations
9.
Allison, Jennifer, Sam Wong, Helen Wong, et al.. (2022). Tivozanib (T) as first-line (1L) treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in North-West of England (NWE), UK.. Journal of Clinical Oncology. 40(6_suppl). 335–335. 1 indexed citations
10.
Vasudev, Naveen, Sarah Brown, Tom Waddell, et al.. (2021). LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM). Annals of Oncology. 32. S1304–S1305. 4 indexed citations
11.
Allison, Jennifer, Natalie Charnley, Robert B. Stevenson, Tom Waddell, & Manon Pillai. (2021). Axitinib and avelumab (AA) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in the Northwest of England, United Kingdom.. Journal of Clinical Oncology. 39(6_suppl). 294–294. 2 indexed citations
12.
Allison, Jennifer, Richard W. Griffiths, Tom Waddell, & Manon Pillai. (2021). Ipilimumab and nivolumab (I+N) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world review in North West of England, United Kingdom.. Journal of Clinical Oncology. 39(6_suppl). 295–295. 1 indexed citations
13.
Gafanov, Rustem, T.B. Powles, Jens Bedke, et al.. (2021). 669P Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study. Annals of Oncology. 32. S694–S694. 5 indexed citations
14.
Rini, Brian I., Elizabeth R. Plimack, V.P. Stus, et al.. (2021). Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.. Journal of Clinical Oncology. 39(15_suppl). 4500–4500. 75 indexed citations
15.
Powles, Thomas, Elizabeth R. Plimack, Denis Soulières, et al.. (2020). Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. The Lancet Oncology. 21(12). 1563–1573. 498 indexed citations breakdown →
16.
Wong, Sam, Tom Waddell, Natalie Charnley, et al.. (2020). Tivozanib as first-line treatment of metastatic renal cell carcinoma: A real-world outcome review in North-West of England, United Kingdom.. Journal of Clinical Oncology. 38(6_suppl). 638–638. 2 indexed citations
17.
Plimack, Elizabeth R., Brian I. Rini, V.P. Stus, et al.. (2020). Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.. Journal of Clinical Oncology. 38(15_suppl). 5001–5001. 46 indexed citations
18.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shruti Shally Saggi Breakdown of academic impact, for papers by Daniel Yick Chin Heng Breakdown of academic impact, for papers by Shaan Dudani Breakdown of academic impact, for papers by Sangeeta Jethwa Breakdown of academic impact, for papers by Omi Parikh Breakdown of academic impact, for papers by Martin Eduardo Richardet Breakdown of academic impact, for papers by Raffaele Ratta Breakdown of academic impact, for papers by Vincenzo Emanuele Chiurì Breakdown of academic impact, for papers by Christina Schiff Breakdown of academic impact, for papers by Chun Loo Gan
Rankless by CCL
2026